Daclizumab for treatment of birdshot chorioretinopathy

Archives of Ophthalmology

Volumn 126, Issue 2, 2008, Pages 186-191

  Sobrin, Lucia ^a   Huang, John J ^a   Christen, William ^b   Kafkala, Chrysanthi ^a   Choopong, Pitipol ^a   Foster, C Stephen ^a  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TRIAMCINOLONE ACETONIDE;

ADULT; CHORIORETINOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; ELECTRORETINOGRAM; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; IMMUNOMODULATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER FUNCTION TEST; MEDICAL RECORD; NIGHT VISION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UVEITIS; VASCULITIS; VISUAL ACUITY; VITREOUS DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; CHORIORETINITIS; ELECTRORETINOGRAPHY; EYE DISEASES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HLA-A ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 39049142656     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archophthalmol.2007.49     Document Type: Review

References (41)

1. Ryan SJ, Maumenee AE. Birdshot retinochoroidopathy. Am J Ophthalmol. 1980;89(1):31-45.
2. Kaplan HJ, Aaberg TM. Birdshot retinochoroidopathy. Am J Ophthalmol. 1980;90(6):773-782.
3. Gass JD. Vitiliginous chorioretinitis. Arch Ophthalmol. 1981;99(10):1778-1787.
4. Fuerst DJ, Tessler HH, Fishman GA, et al. Birdshot retinochoroidopathy. Arch Ophthalmol. 1984;102(2):214-219.
5. Priem HA, Oosterhuis JA. Birdshot chorioretinopathy: clinical characteristics and evolution. Br J Ophthalmol. 1988;72(9):646-659.
6. Nussenblatt RB, Mittal KK, Ryan S, et al. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol. 1982;94(2):147-158.
7. Priem HA, Kijlstra A, Noens L, et al. HLA typing in birdshot chorioretinopathy. Am J Ophthalmol. 1988;105(2):182-185.
8. LeHoang P, Ozdemir N, Benhamou A, et al. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol. 1992;113(1):33-35.
9. Levinson RD, Rajalingam R, Park MS, et al. Human leukocyte antigen A29 subtypes associated with birdshot retinochoroidopathy. Am J Ophthalmol. 2004;138(4):631-634.
10. Oh KT, Christmas NJ, Folk JC. Birdshot retinochoroiditis: long term follow-up of a chronically progressive disease. Am J Ophthalmol. 2002;133(5):622-629.
11. Rothova A, Berendschot TT, Probst K, et al. Birdshot chorioretinopathy: longterm manifestations and visual prognosis. Ophthalmology. 2004;111(5):954-959.
12. Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005;112(6):1066-1071.
13. Thorne JE, Jabs DA, Peters GB, Hair D, Dunn JP, Kempen JH. Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol. 2005;140(1):45-51.
14. Becker MD, Wertheim MS, Smith JR, Rosenbaum JT. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm. 2005;13(4):289-293.
15. Caspi RR, Roberge FG, McAllister CG, et al. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol. 1986;136(3):928-933.
16. Okada AA, Sakai J, Usui M, et al. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm. 1998;6(2):111-120.
17. Guex-Crosier Y, Raber J, Chan C-C, et al. Humanized antibodies against the α-chain of the IL-2 receptor and against the β-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. 1997;158(1):452-458.
18. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338(3):161-165.
19. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A. 1999;96(13):7462-7466.
20. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003;110(4):786-789.
21. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis. Ophthalmology. 2005;112(5):764-770.
22. bright regulatory NK cells in patients with active uveitis. J Immunol. 2005;174(9):5187-5191.
23. Jobin D, Thillaye B, de Kozak Y, et al. Severe retinochoroidopathy: variations of humoral and cellular immunity to S-antigen in a longitudinal study. Curr Eye Res. 1990;9(suppl):91-96.
24. Boisgerault F, Khalil I, Tieng V, et al. Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from retinal soluble antigen, a candidate autoantigen in birdshot retinopathy. Proc Natl Acad Sci U S A. 1996;93(8):3466-3470.
25. Levinson RD, Brezin A, Rothova A, Accorinti M, Holland GN. Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol. 2006;141(1):185-187.
26. Harper SL, Chorich LJ, Foster CS. Diagnosis of uveitis. In: Foster CS, Vitale AT, eds. Diagnosis and Treatment of Uveitis. Philadelphia, PA: WB Saunders Co; 2002: 79-103.
27. Marmor MF. An updated standard for clinical electroretinography. Arch Ophthalmol. 1995;113(11):1375-1376.
28. Jabs DA, Nussenblatt RB, Rosenbaum JT; The Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol. 2005;140(3):509-516.
29. Sobrin L, Lam BL, Liu M, et al. Electroretinography monitoring in birdshot chorioretinopathy. Am J Ophthalmol. 2005;140(1):52-64.
30. Zacks DN, Samson CM, Loewenstein J, et al. Electroretinograms as an indicator of disease activity in birdshot retinochoroidopathy. Graefes Arch Clin Exp Ophthalmol. 2002;240(8):601-607.
31. Holder GE, Robson AG, Pavesio C, Graham EM. Electrophysiological characterisation and monitoring in the management of birdshot chorioretinopathy. Br J Ophthalmol. 2005;89(6):709-718.
32. Fishman GA, Chappelow AW, Anderson RJ, et al. Short-term intervisit variability of ERG amplitudes in normal subjects and patients with retinitis pigmentosa. Retina. 2005;25(8):1014-1021.
33. Birch DG, Anderson JL. Standardized full-field electroretinography: normal values and their variation with age. Arch Ophthalmol. 1992;110(11):1571-1576.
34. Gordon LK, Goldhart R, Holland GN, et al. Standardized visual field assessment for patients with birdshot chorioretinopathy. Ocul Immunol Inflamm. 2006;14(6):325-332.
35. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation. 1999;67(1):110-115.
36. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004;77(2):166-176.
37. Zenapax (daclizumab) [drug label]. Nutley, NJ: Hoffman-LaRoche Laboratories Inc; 2005.
38. Hershberger RE, Starling RC, Eisen HJ. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med. 2005;352(26):2705-2713.
39. Kobashigawa J, David K, Morris J, et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc. 2005;37(2):1333-1339.
40. Petrikovits E, Bedanova H, Necas J, et al. Daclizumab in the induction phase of immunosuppression in heart transplant recipients. Ann Transplant. 2005;10(3):5-10.
41. Nussenblatt RB, Thompson DJS, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21(3):283-293.